An overview of pharmacotherapy-induced ototoxicity

South African Family Practice

Volumn 55, Issue 4, 2013, Pages 357-365

  Schellack, Natalie ^a   Naude, Alida ^a  

^a SEFAKO MAKGATHO HEALTH SCIENCES UNIVERSITY   (South Africa)

Author keywords

Cochleotoxicity; Hearing loss; Otoprotection; Ototoxicity; Pharmacotherapy; Vestibulotoxicity

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BUMETANIDE; CARBOPLATIN; CISPLATIN; ERYTHROMYCIN; FUROSEMIDE; GENTAMICIN; KANAMYCIN; LOOP DIURETIC AGENT; MACROLIDE; MITOCHONDRIAL DNA; NEOMYCIN; NETILMICIN; NONSTEROID ANTIINFLAMMATORY AGENT; QUININE; SPECTINOMYCIN; STREPTOMYCIN; TOBRAMYCIN; TORASEMIDE;

ANATOMICAL VARIATION; AUDITORY SYSTEM EXAMINATION; AWARENESS; BACTERIAL INFECTION; CELL DEATH; COCHLEA PROSTHESIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSPORT; EAR PROTECTION; EVOKED BRAIN STEM AUDITORY RESPONSE; GENETIC PREDISPOSITION; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HAIR CELL; HEARING AID; HEARING IMPAIRMENT; HEART EDEMA; HUMAN; HYPERCALCEMIA; HYPERTENSION; INTERDISCIPLINARY COMMUNICATION; KIDNEY DYSFUNCTION; LIVER DISEASE; MALARIA; MORBIDITY; MYOTONIA; OLIGURIA; OTOACOUSTIC EMISSION; OTOTOXICITY; PHYSICIAN ATTITUDE; PROFESSIONAL COMPETENCE; PROFESSIONAL KNOWLEDGE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEPSIS; SIGNAL TRANSDUCTION; THERAPY; TINNITUS; TUBERCULOSIS; VERTIGO; VESTIBULAR REHABILITATION THERAPY;

EID: 84883670222     PISSN: 20786190     EISSN: 20786204     Source Type: Journal    
DOI: 10.1080/20786204.2013.10874377     Document Type: Review

References (32)

1. Handelsman JA. Vestibulary ototoxicity: the importance and pragmatics of monitoring. Seminars in Hearing/Volume. 2011;32 (3):262-272.
2. Selimoglu E. Aminoglycoside-induced ototoxicity. Curr Pharm Des. 2007;13(1):119-126.
3. Stach BA. Clinical audiology: an introduction. Delmar: Singular Publishing Group; 1998.
4. Hall JW. Handbook of otoacoustic emissions. Stamford: Thomson Learning; 2000.
5. Hall JW. New handbook of auditory evoked responses. Boston: Pearson Education; 2007.
6. Rutka J. Physiology of the vestibular system. Ototoxicity. In: Rutka PS, Rutka J., editors. Ontario: Hamilton; 2004.
7. Steyger PS. Mechanisms involved in ototoxicity. Seminars in Hearing/Volume. 2011;32 (3):217-228.
8. Mathers DM, Fat DM, Boerma JT, World Health Organization. The global burden of disease. World Health Organization. Geneva: WHO; 2008.
9. Vergnano S, Sharland M, Kazembe P, et al. Neonatal sepsis: an international perspective. Arch Dis Child Fetal Neonatal Ed. 2005;90(3):F220-F224.
10. Huth ME, Ricci AJ, Cheng AG. Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. Int J Otolaryngol. 2011;2011:937861.
11. Steyger PS, Hongzhe L. Systemic aminoglycosides are trafficked via endolymph into cochlear hair cells. Sci Rep. 2011;1:159.
12. Knight KR, Kraemer DF, Winter C, Neuwelt EA. Early changes in auditory function as a result of platinum chemotherapy: use of extended high frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol. 2007;10 (25):1190-1195.
13. Sturgeon J. Clinical uses of cisplatin. Ototoxicity. In: Rutka PS, Rutka JA, editors. Ontario: Hamilton; 2004.
14. Gratton MA, Smyth BJ. Ototoxicity of platinum compounds. Ototoxicity. In: Rutka PS, Rutka J., editors. Ontario: Hamilton; 2004.
15. Scott AR, Rutka JA. Macrolides. Ototoxicity. In: Rutka PS, Rutka JA, editors). Ontario: Hamilton; 2004.
16. Umstead GS, Neumann KH. Erythromycin ototoxicity and acute psychotic reaction in cancer patient with hepatic dysfunction. Arch Inter Med. 1986;146(5):879-899.
17. Bizak ED, Houg MT, Schilz RJ, et al. Intravenous azithromycin-induced ototoxicity. Pharmacotherapy. 1999;19(2):245-248
18. th ed. Cape Town: Health and Medical Publishing Group; 2010.
19. Baldwin KA, Budzinski CE, Shapiro CJ. Acute sensorineural hearing loss: furosemide ototoxicity revisited. Hospital Pharmacy. 2008;43(12):982-987.
20. Prepageran N, Scott AR, Rutka JA. Ototoxicity of loop diuretics. Ototoxicity. In: Rutka PS, Rutka J., editors. Ontario: Hamilton; 2004.
21. Hoshino T, Tabuchi K, Hara A. Effects of NSAIDs on the inner ear: possible involvement in cochlear protection. Pharmaceuticals. 2010;3:1286-1295.
22. Prepageran N, Rutka JA. Salicylates, nonsteroidal anfi-inflammatory drugs, quinine and heavy metals. Ototoxicity. In: Rutka PS, Rutka JA, editors. Ontario: Hamilton; 2004.
23. Campbell KCM. Pharmacology and ototoxicity for audiologists. Albany: Thompson Delmar Learning; 2006.
24. Konrad-Martin D, Helt WJ, Reavis KM, et al. Ototoxicity: early detection and monitoring. ASHA Leader. 2005;1:11-14.
25. American Academy of Audiology. Position statement and clinical practice guidelines: ototoxicity monitoring [homepage on the Internet]. 2009. Available from: www.audiology.org/resources/documentlibrary/Documents/OtoMonPositionGuideline.pdf
26. Lonsbury-Martin BL, Martin GK. Evoked otoacoustic emissions as objective screeners for ototoxicity. Seminars in Hearing. 2001;22:377-391.
27. Norton SJ. Cochlear function and otoacoustic emissions. Seminars in Hearing. 1992;13:1-14.
28. Beattie RC, Kenworthy OT, Luna CA. Immediate and short-term reliability of distortion-product otoacoustic emissions. In J Audiol. 2003;42(6):348-354.
29. Knight KR, Kraemer DF, Winter C, Neuwelt A. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol. 2007;25(10):1190-1195.
30. Fischel-Ghodsian N. Genetic factors in aminoglycoside toxicity. Ann N Y Acad Sci. 1999;884:99-109.
31. Kisilevsky VE, Tomlinson RD, Ranalli P, Prepageran N. Monitoring vestibular ototoxicity. Ototoxicity. In: Rutka PS, Rutka J., editors. Ontario: Hamilton; 2004.
32. Jacobson GP, Newman CW, Kartush JM. Handbook of balance function testing. St Louis: Mosby Year Book; 2003.